Galderma is certainly the heavyweight for rosacea treatments and skincare. Rosacea sufferers will be familiar with Metrogel 1% and Oracea as well as their Cetaphil skincare range. More recently Galderma has gained approval for Mirvaso and also has CD5024/Ivermectin in development.
Soolantra is now visible to Doctors and Pharmacists in Australia and stock is expected to be available in a week’s time on the 17th of November. Soolantra Cost Soolantra will be available as a private prescription meaning that you won’t be eligible for concessions and will need to pay the full private price. Pricing information […]
As rosacea sufferers we are most familiar with the consumer side of medicine – we see our doctor, get a prescription and head to the pharmacy. But behind all that medicine is a commercial enterprise working to secure our prescription (and insurance) dollars. When a new treatment enters the rosacea market, the treatment will need […]
Continuing its tradition of launching new prescription products with names unique to Canada, Galderma Canada has announced that the Ivermectin based treatment known as Soolantra in the US will be known as Rosiver in Canada. In Canada, Mirvaso is known as ONRELTEA, and Oracea is known as Apprilon. The full product monograph, including the consumer notes […]
Following on from the large trial announcement by Actavis last year, Galderma has started a suit against Actavis to prevent the sale of Generic Mirvaso. Actavis has filed an abbreviated new drug application with the FDA. Galderma is seeking to use a series of patents to block Actavis from marketing their Brimonidine Topical Gel, 0.33%. […]
Coinciding with the launch of the official web site for Soolantra, Galderma has made available a savings card for Soolantra. The card will allow a potential reduction in any out-of-pocket expenses for a Soolantra prescription, for insured patients. This savings card is similar in operation to Galderma’s cost reduction card for Mirvaso. The terms and […]